https://med.umn.edu/news-events/u-m-medical-school-receives-15m-launch-nation%E2%80%99s-first-ivermectin-covid-19-treatment-clinical-trial
Why is this study being done?
To prevent Long-Covid and reduce symptoms:
COVID-19 increases inflammation in the body, which causes harm.
The medications Metformin, Ivermectin, and Fluvoxamine are known to decrease inflammatory proteins (cytokines) in the body. They also appear to stop the proteins inside cells that help viruses reproduce and spread.
Reviews of persons who developed COVID-19 while taking metformin suggest they were less likely to be hospitalized or die from the infection. Smaller, prospective studies showed patients given fluvoxamine or ivermectin were similarly less likely to be hospitalized or die from COVID-19.
If we give metformin, ivermectin, fluvoxamine, or a combination of these medications to individuals soon after they develop COVID-19, will it decrease the severity of their symptoms? Will it prevent them from needing hospitalization? This study hopes to answer these questions!